PI3K inhibitor BKM120

DRUG4 trials

Sponsors

Roswell Park Cancer Institute, City of Hope Medical Center, University of Chicago, Kami Maddocks, MD

Conditions

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone Lymphoma

Phase 1

PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic

CompletedNCT01540253

Roswell Park Cancer InstituteUnspecified Adult Solid Tumor, Protocol Specific

Start: 2012-05-31End: 2016-06-30Updated: 2022-07-22

PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer

CompletedNCT01723800

City of Hope Medical CenterRecurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer

Start: 2013-07-31End: 2016-09-30Updated: 2016-09-20

PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

CompletedNCT01816984

University of ChicagoMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer +33

Start: 2013-05-31End: 2020-09-30Updated: 2021-10-05

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

CompletedNCT02049541

Kami Maddocks, MDExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma +6

Start: 2014-07-21End: 2019-04-09Updated: 2022-06-30

Related Papers

A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Targeted Oncology2023-10-2513 citations

A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent/metastatic head and neck cancer.

Journal of Clinical Oncology2017-05-202 citations